In " Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how ...

MILAN — Is chronic lymphocytic leukemia (CLL) progression primarily driven by genetic mutations or by external cues from the tumor microenvironment? Despite major strides in targeted therapies, CLL ...

Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...

People with chronic lymphocytic leukemia (CLL) saw a 55% year-to-year increase in all-cause mortality in the early days of the pandemic, a Swedish study found. The study also highlighted a need for ...

Venetoclax demonstrated a 91% overall response rate and 44% complete response rate in octogenarians with CLL, comparable to younger cohorts. Common adverse events included neutropenia (37%) and grade ...

(RTTNews) - BeOne Medicines Ltd. (ONC) Thursday announced it presented new clinical data at the 2025 European Hematology Association or EHA Congress, highlighting the potential of its next-generation ...

Personalized exercise guidance is needed for people living with Chronic Lymphocytic Leukemia (CLL), the most common type of blood cancer, according to a new study led by the University of Surrey. The ...